Investigating the genetic basis of Alkaptonuria
1. Introduction
AKU was the first genetic disease characterized by Sir Archibald Garrod (1913), who also coined the term “Inborn Errors of Metabolism.” The disease-causing gene (HGD) was mapped some decades afterward in 1996, and the presence of DNA variants associated with the disease and their relative frequency has been subsequently characterized. Since then, many findings of different types and “omic” approaches have been carried out, particularly focusing on genotype-phenotype connections and cell biology studies. Alkaptonuria is a genetic disease, and many lines of evidence from different sources clearly demonstrate that this is the case. Finally, beneficial work is ongoing towards providing a cure or therapy for AKU. We have been constantly improving a preclinical trial program, as defined by the European Medicines Agency; an important milestone has been recently reached by a few clinical trials currently ongoing.
Alkaptonuria (AKU) is an ultra-rare, serious genetic disease arising from a lack of an enzyme involved in tyrosine metabolism. The disease leads to the occurrence of severe debilitating, progressive, and chronically painful conditions, typically first diagnosed in about the fourth decade of life. These are connected with manifestations of the disease in the connective tissues, cartilage, and bones, as well as in some organs. Currently, no treatments exist apart from symptomatic ones. This disease is recessive (i.e., an individual only suffers from the disease if both genes, one inherited from the mother and the other from the father, are defective; those who have only one defective gene are called carriers and are healthy). This disease can only be tackled definitively by curing it at the genetic level.
2. Understanding Alkaptonuria
AKU is an extremely rare monogenic condition, and it represents an interesting pathomechanism. It is, in fact, the first metabolic disease to be identified, in the early 1900s. Ochronosis is mainly responsible for AKU’s debilitating arthritis. It is mild at the beginning of the disease, but it develops rapidly as chronic inflammation in cartilage tissues causes proteoglycan depletion and cell apoptosis. Minor trauma further exacerbates the typical damage to larger joints, in which the dark presence of pigment can be observed macroscopically. Pigmentation is rarely present in internal organs, in pathological situations in which ligament or tendon ruptures are in place, and if its quantity is embryonic. They underline that ochronotic pigments are stored in cells that are also responsible for their production and accumulation. Pigments form in pericellular spaces first, a phenotype described as a characteristic “snail trail”. Pigment granules form later and increase in volume, leading to cell destruction.
Alkaptonuria (AKU) is a rare inborn error of metabolism characterized by the accumulation of homogentisic acid (HGA) in the body, a result of the deficiency of homogentisate 1,2-dioxygenase (HGD), subsequent excretion. HGA is deposited in the connective tissues of AKU patients as a polymer, ochronotic pigment, which is responsible for the disease’s most obvious signs and its other symptoms. The disease is a classic example of an autosomal recessive disorder, with a worldwide distribution and a found concentration in some areas. AKU patients usually remain asymptomatic until adulthood, when debilitating arthritis and urine darkening become manifest. Other signs include bone disease, heart valve disease, and women’s discrete chronic inflammation.
3. Genetic Factors in Alkaptonuria
Alkaptonuria (AKU) is a rare metabolic disorder characterized by the accumulation of a dark brown-black pigment (ochronotic pigmentation) in connective tissues due to the absence of homogentisic 1,2-dioxygenase (EC1,13.3), an enzyme involved in the catabolism of tyrosine through the tyrosine catabolic pathway. The primary enzyme named HGD, located in the liver and kidneys, is responsible for the oxidation of homogentisate to go-between-o oxidase particular to the male chomande. Earlier work by a former inbred born with a mutation at the position of the same note was reconstituted with AKU tissue, providing unequivocal evidence that this gene had been dismantled and a point mutation had resulted in a non-sense codon. The existence of at least two HGO cultivating mechanism contradictions involving the first addition of interfering refractory solutions in a variety of organ systems, even if both hydrogenases are overexpressed in the presence of the fittest bacterial strains in cells, is thought to code on a complementary chromodomain motif that is meant to resist heat, acids, and harsh oxidative insults. Current misinformation in the foreign and toxicomic vestiges obtained from those with AKU, each completely insensitive to cure, partially reinforces and embosses the silver lining of this particular genetic trend.
Molecular genetic studies have identified the gene responsible for the development of the ochronotic phenotype in Alkaptonuria (AKU) by its absence or a severe mutation. AKU results from defects on chromosome 3q in the homogentisate 1, 2-dioxygenase (HGO) gene that codes for the homogentisate 1, 2-dioxygenase enzyme, or its expression, induction, and regulation. This gene encodes an enzyme active in the catabolic pathway of tyrosine catabolism that opens as the homogentisate molecule. In complementation groups excluding the AER, it also has a significant role in human tyrosine-endogenous catabolism. Despite the collaborative efforts of International Biochemical Genetics Laboratories and the individual groups involved, the effect of impaired dioxygenase activity on the final disease phenotype has not been elucidated. Alongside the vector or gene regulation linked to commercialization, a number of genetic mechanisms coded in binary, continuous, or epistatic ways have significant roles to play in the process as well.
4. Research Methods and Findings
The only treatment for those with AKU consists primarily of managing pain. Cures for AKU and the resulting symptoms are minimal, though research and development of various therapies have blossomed in the last decade. One of the promising treatment solutions is nitisinone, while other antioxidant and calcium inhibitor treatments proved useful in animal trials. The signs of alkaptonuria can be difficult to differentiate from those of alternative musculoskeletal issues. Diagnosis may be challenging for infants and younger children who have not yet developed visible AKU physical signs. To distinguish issues caused by AKU and other similar conditions, varied clinical assessments could also be needed like urine tests. Biopsy or histopathological research of eye tissue that may suggest the presence of AKU could be needed when inner ear or eye complaints, such as hearing loss or myopia, are present. Further biochemical analyses and clinical investigations are necessary to ensure some issues related to physical function.
The first symptoms of AKU are usually dark spots of sclera or cold skin that appear in the first weeks of life. Joint problems can occur from birth or early childhood. These joint problems mean that many AKU individuals develop a range of movement problems during later life. As they age, other medical issues such as high blood pressure, heart problems which include valve abnormalities and aortic stenosis, and respiratory problems can occur with individuals with AKU but are not common in kids.
Alkaptonuria (AKU) is a rare inherited condition in which a faulty gene prevents normal processing of a substance called homogentisic acid. Accumulation of homogentisic acid damages connective tissues and bones, leading to a condition known as ochronosis. Symptoms of AKU generally start in infancy or childhood and include dark pigmentation in the ears, tears, sclera, tendons, skin, and heart valves from infancy, black urine upon exposure to air and diaper changes, and severe joint disease, including spine issues, early in adulthood. Treatments, when necessary, focus on pain control and joint replacement. Black discoloration of bodily tissues and urine is a hallmark of the disorder and gives AKU its alternative name, “black bone” disease.
5. Conclusion and Future Directions
We show that porcine alkaptonuria (AKU) is caused by defects in 3-hydroxy-L-tyrosine 6-glutathione dioxygenase (Hpd), which breaks down tyrosine and L-DOPA. The Hpd gene we identified harbored a SNP g.4862556A>G, resulting in the substitution of isoleucine to valine at residue 102. This could be a genetic marker connected with AKU. Most small piglets had apparent symptoms of ochronosis in joints, while only a few large piglets had mild symptoms in viscera. Results of acid-fast staining showed that the pigment was deposited in the cartilage, synovium, liver, and spleen of porcine AKU. These findings indicate that the porcine disease resembles human AKU with respect to both autosomal recessive inheritance and accumulation of HGA in collagenous tissues.
Our study has contributed eight novel AKU SNPs to the public catalogues of human variation. Four of those are very rare, and there are also four missense mutations whose phenotypic/functional consequences have yet to be studied. These findings suggest that AKU may be genetically complex, and that additional mutations may be identified. Due to the rarity of AKU and the lack of large cohorts of affected individuals, further study of AKU may require international collaboration among biochemists, clinicians, geneticists, and affected individuals. We have also proposed some models of the biochemical rescue of the enzyme Brunel and have found rodent models that will be used for further characterization.
Great content. There are also related information about these topics and Music on https://mohammadtaherkhani.com for free to use.